Accéder au contenu
Merck

Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease.

Neurobiology of disease (2014-12-24)
Ilse S Pienaar, Cecilia Heyne Lee, Joanna L Elson, Louisa McGuinness, Stephen M Gentleman, Raj N Kalaria, David T Dexter
RÉSUMÉ

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has become an accepted treatment for motor symptoms in a subset of Parkinson's disease (PD) patients. The mechanisms why DBS is effective are incompletely understood, but previous studies show that DBS targeted in brain structures other than the STN may modify the microvasculature. However, this has not been studied in PD subjects who have received STN-DBS. Here we investigated the extent and nature of microvascular changes in post-mortem STN samples from STN-DBS PD patients, compared to aged controls and PD patients who had not been treated with STN-DBS. We used immunohistochemical and immunofluorescent methods to assess serial STN-containing brain sections from PD and STN-DBS PD cases, compared to similar age controls using specific antibodies to detect capillaries, an adherens junction and tight junction-associated proteins as well as activated microglia. Cellular features in stained sections were quantified by confocal fluorescence microscopy and stereological methods in conjunction with in vitro imaging tools. We found significant upregulation of microvessel endothelial cell thickness, length and density but lowered activated microglia density and striking upregulation of all analysed adherens junction and tight junction-associated proteins in STN-DBS PD patients compared to non-DBS PD patients and controls. Moreover, in STN-DBS PD samples, expression of an angiogenic factor, vascular endothelial growth factor (VEGF), was significantly upregulated compared to the other groups. Our findings suggest that overexpressed VEGF and downregulation of inflammatory processes may be critical mechanisms underlying the DBS-induced microvascular changes.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Peroxyde d'hydrogène solution, contains inhibitor, 30 wt. % in H2O, ACS reagent
Sigma-Aldrich
Peroxyde d'hydrogène solution, 30 % (w/w) in H2O, contains stabilizer
Sigma-Aldrich
Peroxyde d'hydrogène solution, 50 wt. % in H2O, stabilized
Sigma-Aldrich
N-Hydroxysuccinimide, 98%
Sigma-Aldrich
Peroxyde d'hydrogène solution, contains inhibitor, 35 wt. % in H2O
Sigma-Aldrich
3,3′-Diaminobenzidine, 97%
Millipore
Peroxyde d'hydrogène solution, 3%, suitable for microbiology
Sigma-Aldrich
Peroxyde d'hydrogène solution, 34.5-36.5%
Sigma-Aldrich
Tris(tert-butoxy)silanol, 99.999%
Supelco
Peroxyde d'hydrogène solution, ≥30%, for trace analysis
Supelco
Citrate de sodium tribasique dihydrate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Peroxyde d'hydrogène solution, contains inhibitor, 30 wt. % in H2O, meets USP testing specifications
Sigma-Aldrich
3,3′-Diaminobenzidine, 97% (HPLC)
Sigma-Aldrich
Citrate Concentrated Solution, BioReagent, suitable for coagulation assays, 4 % (w/v)
Sigma-Aldrich
Citrate Concentrated Solution, BioUltra, for molecular biology, 1 M in H2O
Supelco
Peroxyde d'hydrogène solution, 30 % (w/w), for ultratrace analysis
Sigma-Aldrich
Citric acid trisodium salt, ≥98% (GC), anhydrous
Sigma-Aldrich
Peroxyde d'hydrogène solution, tested according to Ph. Eur.
Sigma-Aldrich
Anti-VE-Cadherin Antibody (CD144), clone BV9, clone BV9, from mouse
Sigma-Aldrich
N-Hydroxysuccinimide, purum, ≥97.0% (T)
Sigma-Aldrich
p-Xylene-bis(N-pyridinium bromide), ≥95% (TLC)